lsc-webmaster

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1 / 2 study of 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in patients with refractory hematologic malignancies or solid tumors. “Opening enrollment on our first

CHICAGO, IL and FORT WORTH, TX, January 15, 2018 – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical study of 9-ING-41, Actuate’s lead agent – a proprietary GSK-3β inhibitor. This initial IND

CHICAGO, IL and FORT WORTH, TX, October 26, 2017 – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to 9-ING-41, Actuate’s lead clinical development candidate, for the treatment of neuroblastoma. The Rare Pediatric Disease Designation of 9-ING for the

CHICAGO, IL and FORT WORTH, TX, April 3, 2017 – Actuate Therapeutics, Inc., a Chicagobased biopharmaceutical company, today announced that an article authored by its scientific founders titled “Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer” was published on March 31, 2017 in the Molecular Pathways special feature in

CHICAGO, IL and FORT WORTH, TX, March 1, 2017 – Actuate Therapeutics, Inc., a Chicago-based biopharmaceutical company, today announced the appointment of Francis J. Giles, MB, MD, FRCPI, FRCPath to the newly created position of Chief Medical Officer (CMO). Dr. Giles will be responsible for advancing Actuate’s research and development initiatives, leading the clinical programs,